Show table of contents · 9 sections▾
This guide is general reference material. It is not legal advice and does not create an attorney–client relationship.
Where Roundup Litigation Stands in 2026
The Roundup litigation is the largest pharmaceutical/product-liability mass tort in modern U.S. history. It began after the World Health Organization's International Agency for Research on Cancer (IARC) classified glyphosate (Roundup's active ingredient) as a probable human carcinogen in 2015. Product-liability cases against Monsanto — acquired by Bayer in 2018 — accumulated rapidly, were consolidated into MDL 2741 in the Northern District of California under Judge Vince Chhabria in 2016, and have been actively litigated ever since.
The Underlying Injury
The dominant qualifying diagnosis in Roundup cases is non-Hodgkin lymphoma (NHL) — a family of blood cancers of the B-cells, T-cells, or NK cells. Specific subtypes with meaningful case volume in the MDL include:
- Diffuse large B-cell lymphoma (DLBCL) — the most common subtype
- Follicular lymphoma
- Marginal zone lymphoma
- Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
- Mantle cell lymphoma
- Burkitt lymphoma
Other cancer types (multiple myeloma, hairy cell leukemia) have been litigated with more mixed results. Non-cancer diagnoses linked to glyphosate exposure remain outside the MDL's core focus.
Exposure Documentation
Because Roundup was one of the most widely used herbicides in the United States, exposure documentation is more accessible than in many product-liability contexts. The MDL has typically accepted three exposure profiles:
- Occupational applicators — landscapers, groundskeepers, farmers, agricultural workers, park and utility maintenance crews. Employment records, purchase orders, timesheets, and OSHA-compliance documents anchor the case.
- Residential heavy users — homeowners who applied Roundup regularly over multiple years. Receipts, credit-card statements, and photographs of product use strengthen the case.
- Adjacent exposures — family members, farmhands, or workers regularly present during application. These cases are harder but litigable with strong documentation.
The Verdict and Settlement History
Several bellwether and non-MDL trials have shaped case value:
- Johnson v. Monsanto (2018, California state court): initial $289 million verdict, reduced on appeal; punitive damages preserved. Established the plaintiff-liability template for the litigation.
- Hardeman v. Monsanto (2019, MDL 2741 bellwether): $80 million verdict, later reduced; upheld by the Ninth Circuit on appeal.
- Pilliod v. Monsanto (2019, California state): $2 billion combined verdict for a husband-wife plaintiff pair; reduced substantially on appeal.
- Multiple post-2020 state trials: mix of plaintiff and defense verdicts. Bayer has won cases as well as lost them, but the pattern has been meaningful plaintiff recoveries where causation is well-documented.
Settlements have proceeded in waves. Bayer announced a $10.9 billion resolution framework in 2020, followed by additional resolution vehicles for later-filed cases. New plaintiffs continue to file, and Bayer has repeatedly signaled willingness to fund additional resolution structures — though case-by-case value depends on diagnosis severity, exposure documentation, and jurisdiction.
What This Means for a Plaintiff Considering Funding
Roundup cases in 2026 fit the typical profile of a mature MDL: individual case timelines running 24–48 months, tier-based resolution structures dominating the settlement math, and case value heavily influenced by diagnosis specifics and exposure documentation. For funding underwriting, the key variables:
- Diagnosis severity. DLBCL with aggressive treatment history typically supports larger advances than an early-stage follicular lymphoma. Cases where the plaintiff has passed away and the case is pursued by the estate follow the same framework but with wrongful-death case-value adjustments.
- Exposure documentation. Occupational applicators with detailed employment records fare better than residential users with sparse documentation.
- Age at diagnosis. Younger plaintiffs — especially those still in productive working years at diagnosis — carry larger damages, particularly around lost earnings and life expectancy adjustments.
- Case posture. Cases filed and moved into the MDL have more predictable timelines than new filings. Cases still in pre-suit typically warrant more conservative underwriting.
For the general framework on funding in MDL contexts, see our companion pieces on funding for class action and mass tort plaintiffs and how funding supports mass-tort plaintiffs. For an active-MDL parallel, see our Hair Relaxer MDL 3060 guide. For the post-settlement disbursement timeline, see the global settlement to individual payout timeline.
The Preemption and Legislative Landscape
Bayer has argued in multiple contexts that federal pesticide labeling law (FIFRA) preempts state failure-to-warn claims. The Supreme Court has considered and declined to weigh in on the specific preemption question in the Roundup context (Monsanto v. Hardeman, cert denied 2022), leaving the matter unresolved as a federal question. State-court preemption analyses have been mixed. This remains one of the most consequential legal risks in the litigation — a favorable preemption ruling could substantially reduce plaintiff recoveries; an adverse one could accelerate the settlement pace. Legislative preemption efforts in Congress and various state legislatures have not passed as of early 2026.
Statute of Limitations
Roundup product-liability statutes of limitations vary by state, typically 2–6 years from diagnosis, with discovery rules that can extend the window. Plaintiffs whose diagnosis is more than a few years old should still consult counsel promptly — discovery-rule analyses often preserve otherwise-stale claims where the link between the herbicide and the diagnosis was not reasonably apparent until later.
The Bottom Line
The Roundup litigation is one of the most active and consequential mass torts in the U.S. legal system. For plaintiffs with a qualifying diagnosis and documented exposure, the case is a real path to compensation on a multi-year timeline. Pre-settlement funding fits precisely into the gap between filing and resolution — providing working capital during the years the case is pending without adding case-outcome risk to a plaintiff already facing serious illness.
At Instabridge Funding, we work with plaintiff attorneys across all fifty states — attorney-founded, non-recourse, and transparently priced. If your case is filed and you would like a fair pre-settlement offer, apply through our portal and your attorney will hear back within one business day.
Frequently asked questions
Yes. New cases continue to be filed. MDL 2741 remains active, and multiple state-court venues also handle Roundup claims.
Primarily non-Hodgkin lymphoma and its subtypes. Other diagnoses (multiple myeloma, hairy cell leukemia) are litigated with more mixed causation outcomes.
Plan for 24–48 months from filing to resolution. Individual timelines vary with diagnosis, exposure documentation, and whether the case is resolved through settlement or trial.
Bayer has publicly disclosed roughly $11 billion in aggregate settlement funding across multiple waves. Individual case values vary widely by diagnosis severity, exposure documentation, and jurisdiction.
Bayer stopped selling glyphosate-based Roundup for U.S. residential use starting in 2023, though professional and agricultural formulations continue. This does not affect litigation over historical exposures.
Yes, once the case is filed and diagnosis documentation is in place. Underwriting reflects diagnosis specifics, exposure history, and case posture.
Estates and survivors may pursue the claim as a survival action and/or wrongful-death claim, subject to state law. Notify counsel promptly for estate substitution.
Health insurance and Medicare pay for medical care during the case. Both may assert subrogation against the settlement. See our companion piece on funding and medical liens.
